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A B S T R A C T
Head and neck cancer is the fifth most common cancer worldwide. It is often amenable to curative
intent therapy when localized to the head and neck region, but it carries a poor prognosis when it
is recurrent or metastatic. Therefore, initial treatment decisions are critical to improve patient
survival. However, multimodality therapy used with curative intent is toxic. The balance between
offering intensive versus tolerable and function-preserving therapy has been thrown into sharp
relief with the recently described epidemic of human papillomavirus–associated head and neck
squamous cell carcinomas characterized by improved clinical outcomes compared with smoking-
associated head and neck tumors. Model systems and clinical trials have been slow to address the
clinical questions that face the field to date. With this as a background, a host of translational
studies have recently reported the somatic alterations in head and neck cancer and have
highlighted the distinct genetic and biologic differences between viral and tobacco-associated
tumors. This review seeks to summarize the main findings of studies, including The Cancer
Genome Atlas, for the clinician scientist, with a goal of leveraging this new knowledge toward the
betterment of patients with head and neck cancer.
J Clin Oncol 33:3227-3234. © 2015 by American Society of Clinical Oncology
INTRODUCTION
Head and neck squamous cell carcinoma (HNSCC)
is the fifth most common nonskin cancer world-
wide; the annual incidence is 600,000 cases, and
50,000 cases are diagnosed annually in the United
States.1,2 Although HNSCC historically was viewed
as a tobacco- and alcohol-related cancer, infection
with high-risk human papillomaviruses (HPVs)
during the past decade has emerged as a risk factor
for a substantial fraction of HNSCCs.3 The so-called
HPV epidemic is most prominent in patients of
Northern European and North American origin,
whereas other areas of the world still see few HPV-
associated tumors.4-6 In studies that include an as-
sessment of HPV status, a shift in the traditional risk
factors is nearly universally noted: viral-associated
tumors are seen in younger populations that have
lymph node–positive oropharyngeal carcinomas
and lower rates of smoking.7 Having said this, most
patients with HPV-associated oropharyngeal carci-
noma are still men in their 50s who have a smoking
history, and true nonsmokers constitute only a
minority.1,3,8-10 Unfortunately, a precise character-
ization of patients with HNSCC by HPV status is
challenging. First, because HPV is not yet part of the
staging system in HNSCC, tumor registries, such as
the Surveillance, Epidemiology, and End Results
(SEER) program, do not routinely record it. Adding
to the knowledge gap is a lack of consensus of diag-
nostic reagents to detect HPV. Variability in the
assays used across studies limits generalizability and
comparability of results.11,12
Although morphologic characteristics, such as
basal squamous histology, poor differentiation, and
absent keratin formation, are associated with HPV
infection, the diagnosis of HPV is made through
molecular testing. A mystery of the disease is that no
precursor lesion on which to screen patients during
the long latency has been reported, despite the as-
sumption that viral exposure occurs via sexual con-
tact in young adulthood. Screening HPV molecular
assays, including polymerase chain reaction–based
techniques, risk false-positive detection of endemic
viral infections not associated with cancer, whereas
specific in situ hybridization (ISH) assays often have
lower sensitivity.13 A useful proxy for HPV infection
in tumors is by immunohistochemistry (IHC) as-
sessment of p16, the protein product of the gene
CDKN2A.14 As shown in Figure 1, p16 is a repressor
of the D cyclins that, in turn, partially phosphorylate
the retinoblastoma tumor-suppressor protein (RB1).
In the setting of viral infection, expression of the E7
viral oncoprotein mediates degradation of RB1, and
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pathway feedback results in overexpression of the cell senescence
pathways, including p16.15 The detection of p16 is a proxy for RB1 loss
through any mechanism, including mutations of RB1 that are not
mediated by E7 or HPV. Therefore, p16 detection can result in the
false assumption that E7 is expressed and, by extension, that the tumor
is HPV positive.16 For instances of high pretest probability for HPV,
such as in squamous cell carcinomas of the oropharynx, the true-
positive rate for p16 as an indication of HPV is high.14 When the
pretest probability is lower, such as in the oral cavity, the true-positive
rate decreases to 10%-41%, which renders p16 IHC an ineffective
diagnostic tool. If it is assumed that 5% of nonoropharynx tumors
are HPV positive, as many as 1,500 cases per year outside the orophar-
ynx may be difficult to assess with p16. Ultimately, direct tests of E6
and E7 may prove superior, but these are not yet routine.17
Although the demographic shifts may be modest between pa-
tients who are HPV positive and HPV negative, clinical outcomes are
dramatically different. Although patients with HPV commonly pres-
ent with advanced nodal disease and clinical stage, prognosis is favor-
able compared with patients without HPV.3 Improved outcomes are
seen across treatment modalities, including chemotherapy, radiation,
chemoradiotherapy, and potentially also surgery, which have led to
proposals to incorporate HPV status in staging.9 Although outcomes
are better, the implications for selection of patient therapy by HPV
status are not yet clear, because few existing clinical trials assessed HPV
status.18-20 Controversies are most pronounced in molecularly targeted
therapy, for which little conclusive published data exist, although retro-
spective studies have been presented in scientific meetings. Two ran-
domized, phase III studies that used anti–epidermal growth factor
receptor (EGFR) therapy either combined with chemotherapy or as a
single agent versus methotrexate suggest less activity of EGFR agents in
p16-positive tumors.21,22 An additional phase II study indicated a 0%
response rate for single-agent anti-EGFR therapy in HPV-associated
HNSCC according to highly accurate E6/E7 RNA-based HPV test-
ing.23 Conversely, in the EXTREME (Erbitux in First-Line Treatment
of Recurrent or Metastatic Head and Neck Cancer) study, a nonsig-
nificant trend toward benefit in patients who were positive by p16
and/or ISH was seen, although analysis was limited because of small
numbers and the use of p16 IHC for nonoropharynx tumors.24 The
phase III trial of cetuximab in combination with radiation favored
outcomes in patients with oropharynx tumors in the cetuximab treat-
ment arm.18 In a retrospective subset analysis, patients with p16-
positive and p16-negative oropharynx tumors benefited from
cetuximab.25 However, analysis that used HPV nucleic acid testing by
ISH did not show a clear benefit, which suggests that p16 expression,
rather than HPV status, may be important. In short, controversy
remains as to whether the combination of cetuximab with radiation
seems to benefit patients with HPV-positive oropharyngeal cancer. By
contrast, the data are stronger that patients who are p16 positive for
HPV may benefit, although such patients include some HPV-
negative, yet p16-positive, tumors. At a molecular level, published
studies suggest an anticorrelation between staining for the EGFR re-
ceptor and benefit of cetuximab.20 HPV-positive tumors have gener-
ally shown low or absent levels of EGFR protein expression or EGFR
gene amplification.1,10 Unfortunately, preclinical models fail to clarify
the picture, because HPV-positive cell lines of HNSCC remain in early
development. Ongoing trials, such as Radiation Therapy Oncology
Group study RTOG 1016 (NCT01302834), may clarify some contro-
versies about cetuximab. Other studies leverage the dramatically
improved outcomes for patients with HPV-positive tumors by de-
escalating therapy and potentially decreasing toxicity.26
In parallel with lessons learned by clinical trials, rapidly emerg-
ing advances in tumor characterization, including DNA sequencing,
RNA sequencing, miRNA characterization, epigenetic characteriza-
tion, and proteomics, are in sight and have been widely reviewed
elsewhere.1,27-34 Data from large cooperative endeavors, such as The
Cancer Genome Atlas (TCGA), and individual efforts, such as the
Chicago HNC Genomics cohorts, have illuminated the genome of
HNSCC in a manner that reveals the most commonly altered genes
and coordinated patterns of genome alteration, which could be lever-
aged to accelerate our understanding of the disease, improve person-
alization of existing therapies to increase effectiveness, and propose



















Fig 1. Role of E6 and E7 in the cell cycle
pathways and gene alterations as a func-
tion of human papillomavirius (HPV) tumor
status. Genes altered in HPV-positive or
viral oncogenes (red) or in HPV-negative
tumors (black). RB, retinoblastoma tumor-
suppressor protein.
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STRUCTURAL ALTERATIONS
Several publications have reported the copy number landscape of
HPV-positive versus HPV-negative HNSCC (Fig 2).1,27-35 Across
much of the genome, the copy number alterations from HPV-positive
and HPV-negative tumors are highly concordant, and shared ampli-
fications are 1q, 3q, 5p, 8q, and others. Common deletions include 3p,
5q, 11q, and others. In some instances, comparison of altered regions
across studies is challenging because of the small number of patients
who are HPV positive. Although many regions are clearly shared,
others are strikingly divergent. Recently, a region on chromosome
14q32 was reported showing deep deletions in HPV-positive tumors
and few, if any, deletions in HPV-negative tumors.1 Focal deletions,
which include homozygous deletions, are relatively rare in a cancer
genome and, when recurrent, are often suggestive of key novel tumor-
suppressor genes. In combination with sequencing data, homozygous
deletions noted in the TCGA study identified that the tumor-
suppressor gene TRAF3 was inactivated in approximately 20% of
HPV-positive tumors; this inactivation had been previously unrecog-
nized in HNSCC, although TRAF3 loss had been seen in nasopharyn-
geal carcinoma.1,36 TRAF3 is implicated in innate interferon and
acquired antiviral responses, including in Epstein-Barr virus, HPV,
and HIV.37-40 TRAF3 also serves as a ubiquitin ligase and negative
regulator for nuclear factor-B (NF-B) –inducing kinase, a criti-
cal signal component in activation of transcription factors, which
are implicated in cell survival and other features of the malignant
phenotype.38
A second deletion that presents more prominently in patients
with HPV-positive tumors occurs in chromosome 11q. Although the
deletion occurs in a broad region, which makes a single gene target
difficult to identify, several prominent tumor-suppressor genes are
suggested, including ATM1. In terms of broad and focal amplification,
perhaps the most prominent difference occurs on chromosome 7,
where HPV-positive tumors exhibit no evidence of amplification. The
prominent focal amplification seen at the locus of EGFR is likewise
absent in HPV-positive tumors.1 The importance of this distinction
for anti-EGFR therapy remains obscure, but the lack of genomic
targeting for amplification is evidence that HPV-positive tumors
do not select for this gene at the clonal level. By contrast, HPV-
positive more so than HPV-negative tumors display a clear prom-
inence of amplification of 3q at the locus for the squamous lineage
transcription factors SOX2, TP63, and the oncogene PIK3CA.
PIK3CA activation promotes activation of cell cycle, metabolism,
and transcription factors that regulate diverse genes that promote
the malignant phenotype.1,2,41
When cell cycle signaling is considered (Fig 1), statistically signif-
icant copy number changes in at least three genes is remarkable. As
expected, chromosome 9p, the locus for the gene CDKN2A which
produces the protein product p16, is frequently lost in HPV-negative
versus HPV-positive tumors. Similarly, HPV-negative tumors dem-
onstrate prominent amplifications of CCND1 (cyclin D), whereas
HPV-positive tumors contain a striking focal amplification at 20q11,
the location of E2F1. The E2F1 gene, which encodes a key transcrip-
tion factor that promotes genes that mediate cell cycle initiation from
G0 to G1 and cell proliferation, is amplified in approximately 20% of
HPV-positive HNSCCs but in only 2% of HPV-negative HNSCCs.1
E2F1 together with tumor-suppressor proteins TP53 and RB1, which
are inactivated by the HPV E6 and E7 oncoproteins, critically deregu-
late cell cycle control and genomic stability in HPV-positive HNSCC.
A fourth gene in the cell cycle pathway, RB1, although only rarely
inactivated, is more often lost in HPV-positive tumors.
At this time, studies have detected only rare instances of activated
fusion oncogenes based on analysis of DNA structural rearrange-
ments. Most prominently, in a minority of HPV-positive samples,
several authors have reported FGFR3-TACC3 fusions that seem
promising as a therapeutic target.42-44 In addition, there was evidence
in single samples for structural alterations associated with MET
activation. Finally, the most well-described alternative transcript of
EGFR, the so-called vIII mutant, was only rarely observed, at a rate
of less than 1%.1
MUTATION SIGNATURE
It is perhaps somewhat surprising that tumors that presumably
have disparate molecular origins as HPV-positive virally associated
tumors and HPV-negative tobacco-associated tumors share as
much homology in their genome landscape as the copy number
data demonstrate. Other similarities between these subtypes in-
clude the generally similar mutation rate and number of copy
number changes in each group. Other aspects of their molecular
signature are, however, distinctly different.
As expected, the transversions associated with smoking in many
tumors (ie, mutations that change a purine nucleotide to another
purine (A↔G) or a pyrimidine nucleotide to another pyrimidine
(C↔T) at CpG sites were more frequent in HPV-negative tumors.1 By
contrast, a more unique signature has recently been reported in HPV-
positive tumors and in some other tumors in which a predominance
of TpC mutations is noted. These cytosine-to-thymidine CT muta-
tions have recently been shown most prominently in virally trans-
formed cancers, in which there is increased cytosine deaminase
mutagenesis that is characteristic of the apolipoprotein B mRNA ed-
iting enzyme catalytic (APOBEC) family of enzymes.45 APOBEC cy-
tosine deaminase activity is induced and has emerged as a potential
mutagenic factor in virally induced human cancers. Indeed, sequence































Fig 2. Copy number alterations by chromosome position in human papilloma-
virus (HPV) –positive and HPV-negative tumors.
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genome-wide cytosine mutations consistent with APOBEC deamina-
tion and edits to the cellular DNA.46,47 The importance of this partic-
ular mutation signature is that it may explain, in part, a striking
pattern seen in the distribution of mutations of one of the key onco-
genes of HNSCC, PIK3CA, between HPV-positive and HPV-negative
tumors. Although PIK3CA is altered in tumors without regard to viral
association, two specific CT mutations in viral-associated tumors
occur predominantly in two hotspots within the helical domain. These
result in E542K and E545K amino acid substitutions that are impli-
cated in PIK3CA kinase and oncogene activation.1,27,45 The specificity
of PIK3CA targeting emphasizes even more strongly the importance
of the 3q locus described in HPV-positive tumors described in the
Structural Alterations section. In smoking-related tumors, PIK3CA
mutations, including variants of unknown significance on signaling,
are seen throughout the gene and are seen much less commonly in the
hot spots. The signature APOBEC mutation of PIK3CA in HPV-
positive HNSCC evokes the well-known transversion mutation of
KRAS (G12C and G12V) in smoking-related lung adenocarcinoma.48
Strikingly, although squamous cell carcinoma of any site rarely
demonstrates KRAS mutations, they are reported in HPV-positive
HNSCC.27 Although the data are sparse, the interaction between
smoking and KRAS mutation suggests a mechanism through which
tobacco might augment risk in HPV-positive HNSCC.
HPV VIRAL INTEGRATION
In addition to the distinct mutational signature (APOBEC v smoking
pattern), HPV-positive tumors are characterized by a second distinct
structural alteration compared with HPV-negative tumors: the inte-
gration of viral DNA. Although the true rate of HPV integration into
the human genome is unknown, existing data suggest that at least two
thirds of patients with high expression of E6 and E7 by RNA quantifi-
cation have detectable integration sites in the genome.49 The exact
nature of the integration is the subject of ongoing investigation. Most
tumors seem to have a single primary integration site, although the
integration event itself may be complex at sites of gene amplification.50
Less common are tumors with multiple insertion sites on different
chromosomes. Most viral integrations occur in or near genes, al-
though the data do not yet support a recurrent site of integration to
identify selective pressure on a specific location in the genome. As with
most structural rearrangements in cancer, the predicted impact
of integration is generally to silence the gene.1 Several tumor-
suppressor genes have documented viral integration sites, such as
RAD51 and ETS2. Whether the integration event resulted in tumor
initiation or progression has not been definitively shown versus the
alternative possibility that the gene disruption may be a passenger
event. In the case of a passenger event, the targeting of a gene may
be nonspecific and may result from a stochastic event that occurred
at any open chromatin location. The lack of recurrent events gives
more weight to the lower relevance of the integration site to tumor
initiation and progression.
MUTATIONS AND PATHWAYS
Among the most anticipated results from recent tumor-profiling proj-
ects was the accounting of driver gene somatic mutations. A driver
gene is defined as a gene that, when mutated, is responsible for either
initiation or progression of a cancer. In the context of cancer sequenc-
ing projects in which mutations cannot be individually tested for their
biologic function, driver mutation status is defined as a mutation that
occurs more often than expected by chance. Many other incidental
mutations, called passenger mutations, occur in the tumor, but these
are attributed to the inherent instability of the cancer genome. Because
the methods to rigorously define driver mutations continue to evolve,
additional factors beyond statistical significance are considered when
the most likely candidates for driver gene status are selected; factors
include whether the gene is mutated at a specific functional position,
the gene has been reported in other cancers, and mutations occur in
conjunction with copy number or other structural alterations. Several
reports with significant numbers of patients sequenced suggest that
most common driver mutations from the overall population of
HNSCC (mutations with a frequency  5% to 10%) have been de-
tected (Table 1).1,27-31 Data remain limited in subpopulations, includ-
ing in HPV-positive tumors, for which the cohorts remain relatively
underpowered for the most rigorous statistical approaches.
Many mutations, along with previously described regions of copy
number and structural alteration, fall into a few cancer pathways.
Most notably, almost every tumor had at least one mutation in the cell
cycle and survival pathway; mutations included CDKN2A (p16) mu-
tations, deletions, and hypermethylation; RB1 mutations and dele-
tions; E2F1 amplification; CCND1 amplification; MYC amplification;
and TP53. The gene CCND1 bears special mention, because it is
among the most frequently altered oncogenes in HNSCC, although
this occurs almost entirely in HPV-negative tumors. By the canonical
pathway representation (Fig 1), it is immediately upstream of CDK4/
CDK6, which is a target of palbociclib, an inhibitor that was recently
approved in breast cancer.51 Trials in HNSCC are ongoing. Interest-
ingly, nearly every HPV-negative tumor has inactivation of CDKN2A,
and most have inactivation of TP53. One notable exception was a
subset of oral cavity cancers that had p16 loss but wild-type TP53.
Tumors in these patients have a strikingly high rate of CASP8 inacti-
vation and concurrent HRAS activating mutations, which suggests a
distinct clinical entity that, in at least one data set, was also associated
with favorable clinical outcomes.1 Other investigators have reported
similar favorable outcomes associated with wild-type TP53 in combi-
nation with other genomic alterations.52 The weight of the evidence,
including the low rate of TP53 in patients with HPV-positive tumors
who also benefit from favorable outcomes, suggests that wild-type
TP53 status might serve as a universal marker of favorable outcome
without regard to HPV status.
A second pathway clearly targeted by multiple driver mutations is
the receptor tyrosine kinase pathway, which includes the RAS,
PIK3CA, and PTEN branches. Numerous targets are altered, includ-
ing activating mutations of PIK3CA, HRAS, FGFR3, KRAS, FGFR2,
EGFR, and KRAS (Fig 3). The EGFR mutations are worthy of special
note, because these are generally not the canonical activating muta-
tions seen in lung cancer in the kinase domain of the gene. Mutations
are more often in the juxtamembrane region of the gene and include a
number that have been documented to be functional in other cancer
types, including glioblastoma. Additional kinase pathway mutations
include loss of function from repressor elements in the pathway;
examples include PTEN, PIK3R1, and NF1.
Relevant to the recent enthusiasm in immune-based therapy
in solid tumors, which includes the recent approval of nivolumab
Hayes, Van Waes, and Seiwert
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in squamous lung cancer, several known or suspected driver mu-
tations in the immune and cell death pathways are demonstrated in
HNSCC.53 Amplifications of FADD and BIRC2, along with loss-of-
function mutations and deletions of CASP8 and TRAF3, highlight a
dependence on the NF-B pathway. Mutations in HLA-A/HLA-B and
B2M are also seen in squamous lung cancer and, although these have
not clearly been functionally validated, represent important candidate
driver mutations. The immune system remains an important area of
investigation through integrated data analysis as well. Investigators
with TCGA demonstrated dramatic differences in immune signa-
tures across the molecular subtypes of HNSCC identified by gene
expression patterns, most notably with a complete absence of
immune infiltration in the classic subtype and an activated T-cell
signature in the mesenchymal subtype.1,54,55
Perhaps more difficult to target with current therapeutics, but
nonetheless frequently altered, are three additional pathways: squa-
mous differentiation, oxidative stress, and WNT signaling. Many tu-
mors demonstrated loss-of-function mutations in NOTCH genes,
almost always with amplifications of chromosome 3q, where the well-
known squamous transcription factor TP63 is located. Perhaps less
well appreciated is the increasingly recognized interaction between
this differentiation pathway and two frequently lost genes of the WNT
pathway, FAT1 and AJUBA.56,57 Several direct interactors with TP63
and NOTCH seem affected by loss of function, including ZNF75058
and, most important as the master regulator of oxidative stress,
NFE2L2.59 It may be fair to say, if early reports are validated, that the
NFE2L2 axis, with its repressors KEAP1 and CUL3, may represent one
of the early potential therapeutic biomarkers for clinical use. Altera-
tions of oxidative stress are seen across the spectrum of smoking-
related cancers and are tightly associated with the classic gene
expression subtype, as has been validated in numerous studies.1,60
Early translational data and preclinical models suggest that activation
of this pathway may be associated with resistance to radiation, which is
a cornerstone of therapy in HNSCC.61,62
Although there are many other mutations, one in particular bears
special attention: the gene for nuclear receptor binding SET domain
protein 1 (NSD1), which is altered in approximately 10% of tumors.
The NSD1 gene is a histone 3 Lys 36 (H3K36) methyltransferase,
similar to SETD2, a gene most associated with alterations in the clear
cell subtype of renal cell carcinoma. Just as with SETD2 in clear cell
carcinoma, mutations of NSD1 were associated with a dramatic,
genome-wide hypomethylation phenotype in HNSCC.1,63 Inter-
estingly, NSD1 seems relevant in relation to head and neck devel-
opment in nonmalignant disease, as do germline inactivating
mutations, which are associated with craniofacial abnormalities
(Sotos syndrome).
INTEGRATED ANALYSIS
In addition to gene sequencing and copy number studies, there are
mounting data from additional genomics platforms relevant to the
understanding of HNSCC. The most mature of these data are gene
expression studies that include microarrays and RNA sequencing
from TCGA. It is now clear that reproducible subtypes of HNSCC can
be defined by expression data, including the classic subtype associated
with activated oxidative stress, the atypical subtype associated with
lack of chromosome 7 amplification (including most HPV-positive
cases), the mesenchymal subtype characterized by an activated T-cell
signature, and the basal subtype associated with wild-type TP53. Mo-
lecular subtypes are an attractive way to classify tumors in some
instances for the purposes of consideration of model systems and
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Data are presented for selected genes with mutation rates  10% in at least
one series.
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of q score  0.1 in at least one study. The gene is reported because the sum
of evidence supports its status as a driver.
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potentially of therapeutic groups, although the clinical utility of this
remains unproved.1 Others have reported predictive gene expression
signatures associated with prognosis, response to therapy, and HPV
status; other phenotypes have been reported but have not generally
been validated in clinical trials. The Chicago HNC Genomics cohort
has recently reported a striking finding within HPV-positive HNSCC
of two subgroups defined as prominent inflamed (inflamed mesen-
chymal HPV-positive subtype) or noninflamed (classic HPV-positive
subtype) with potential implications for immunotherapy.1,10 Similar
work has been reported with other biomolecule platforms that target
epigenetics, miRNA, and proteomics.
OUTLOOK AND FUTURE CLINICAL IMPLICATIONS
As a first step, accurate HPV diagnostics are needed beyond the
interim proxy biomarker of p16. With confidence in the diagnosis
of virally associated tumors will come a definitive answer about the
effectiveness of cetuximab as a function of HPV status and confi-
dence in making HPV-related treatment decisions in the future
(eg, de-escalation). Furthermore, the increased breadth of
genomic data on EGFR and related pathway alterations invites a
re-evaluation of predictive biomarkers of EGFR-directed thera-
pies. Extension of the molecular profiling beyond HPV status to
target the most common molecular alterations for both therapeu-
tic and prognostic indications will become possible if profiling is
done routinely (eg, associated with clinical studies). Two immedi-
ately obvious candidates include the PIK3CA and CDK4/CDK6
pathways because of the high prevalence of PIK3CA mutations and
CCND1 amplifications and the availability of existing therapeutics.
Beyond targeted therapies, preclinical data already suggest that
adherent signaling in the NFE2L2 pathway may predict differential
phenotypes with respect to standard chemotherapy and radiation
in ways that have clinical relevance, such as the selection of primary
treatment modality. Other broad signatures, such as molecular
subtypes predicted by expression profiling, might similarly influ-
ence the selection of therapies, such as immune-based treatment,
and new technologies will allow reliable and reproducible determi-
nation of expression signatures as part of clinical trials. The discov-
ery of molecular signatures and shared mutations across tumor
types, such as squamous lung cancer and esophageal cancer, offers
the potential to unify treatment paradigms across cancers that have
historically been isolated by anatomic boundaries. Among the
barriers that face clinicians and researchers in achievement of the
promise of molecular characterization of HNSCC is uncertainty in
the regulatory and reimbursement environment for molecular di-
agnostics. The pace of progress may be determined, in large part, by
the ability of researchers and clinicians to order (and justify to
payers or trial sponsors) the relevant clinical grade diagnostic tests
to fuel molecularly targeted clinical trials and population studies.
In conclusion, head and neck cancer is a common and often
fatal cancer that is typically treated with curative intent at the time
of diagnosis. Many therapeutic questions, including the choice of
optimal treatment modality and intensity and implications of HPV
status on therapy, remain. By using the data provided by the first
wave of comprehensive genome characterization, studies should

































































































































Fig 3. Frequent genetic aberrations in selected pathways altered in HPV-positive (A) and HPV-negative (B) head and neck squamous cell carcinoma. Overview of key
genetic aberrations for HPV-positive and HPV-negative head and neck cancers. Shades of gold indicate frequency of activating changes in presumed oncogenes, and
shades of blue indicate frequency of inactivating changes in presumed tumor suppressor genes. amp, amplification; del, deletion; HLA, human leukocyte antigen; mut,
mutation; fus, fusion/translocation; wt, wild type.
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frequent gene alterations in the disease. Researchers will be able to
leverage this knowledge in the design of clinical trials, the develop-
ment of model systems, and the assessment of patient outcomes.
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